Ashley Ringrose

Learn More
BACKGROUND Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate IM response of primitive CML cells, but the effect of the interaction complex on the response to ABL and JAK2 inhibitors is unknown. METHODS(More)
Chronic myeloid leukemia (CML) represents the first human malignancy successfully treated with a tyrosine kinase inhibitor (TKI; imatinib). However, early relapses and the emergence of imatinib-resistant disease are problematic. Evidence suggests that imatinib and other inhibitors may not effectively eradicate leukemic stem/progenitor cells, and that(More)
Imatinib mesylate (IM) induces clinical remissions in chronic-phase chronic myeloid leukemia (CML) patients but IM resistance remains a problem. We recently identified several features of CML CD34(+) stem/progenitor cells expected to confer resistance to BCR-ABL-targeted therapeutics. From a study of 25 initially chronic-phase patients, we now demonstrate(More)
AHI-1 is an oncogene often targeted by provirus insertional mutagenesis in murine leukemias and lymphomas. Aberrant expression of human AHI-1 occurs in cutaneous T-cell lymphoma (CTCL) cells and in CD4(+)CD7(-) Sezary cells from patients with Sezary syndrome. Stable knockdown of AHI-1 using retroviral-mediated RNA interference in CTCL cells inhibits their(More)
Ahi-1 (Abelson helper integration site 1) is a novel gene frequently activated by provirus insertional mutagenesis in murine leukemias and lymphomas. Its involvement in human leukemogenesis is demonstrated by gross perturbations in its expression in human leukemia cells, particularly in cutaneous T-cell lymphoma cell lines where increases in AHI-1(More)
We describe an optical technique for detecting and monitoring antibody-antigen reactions at a solid-liquid interface. The antibody is covalently immobilized onto the surface of either a planar (microscope slide) or cylindrical (fibre optic) waveguide made of fused quartz. The reaction of immobilized antibody with antigen in solution is detected through use(More)
Imatinib mesylate (IM) induces clinical remissions in chronic-phase chronic my-eloid leukemia (CML) patients but IM resistance remains a problem. We recently identified several features of CML CD34 ؉ stem/progenitor cells expected to confer resistance to BCR-ABL-targeted therapeu-tics. From a study of 25 initially chronic-phase patients, we now demonstrate(More)
  • 1